



Sevelamer carbonate Zentiva

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
X/0011	Annex I_2.(c) Change or addition of a new strength/potency	26/07/2018	20/09/2018	SmPC, Labelling and PL	
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	25/07/2018	20/09/2018	PL	
PSUSA/2697/201710	Periodic Safety Update EU Single assessment - sevelamer	14/06/2018	n/a		PRAC Recommendation - maintenance

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



WS/1383	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>B.II.f.1.e - Stability of FP - Change to an approved stability protocol</p>	07/06/2018	n/a		
IG/0926/G	<p>This was an application for a group of variations.</p> <p>A.7 - Administrative change - Deletion of manufacturing sites</p> <p>B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)</p> <p>B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition</p>	06/06/2018	n/a		
WS/1332	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of sections 4.2 and 6.6 of the SmPC in order to include the use of food and beverage as an alternative to water for administration of sevelamer carbonate powder for oral suspension.</p> <p>The Package Leaflet is updated accordingly.</p> <p>In addition, the Worksharing applicant (WSA) took the opportunity to revise the Annex A.</p>	22/02/2018	20/09/2018	SmPC and PL	

	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data				
N/0012	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/12/2017	20/09/2018	Labelling and PL	
IG/0844	C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority	22/09/2017	20/09/2018	SmPC, Labelling and PL	
IG/0804/G	This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size	26/06/2017	n/a		
WS/0965	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Extension of indication for Renvela 1.6 g and 2.4 g powder for oral suspension and Sevelamer carbonate Zentiva 2.4 g powder for oral suspension to include the control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area (BSA) of >0.75 m ²) with chronic kidney disease. As a consequence, sections 4.2, 4.8 and 5.1 of the SmPC	18/05/2017	23/06/2017	SmPC and PL	Please refer to the Scientific Discussion of Renvela and Sevelamer carbonate Zentiva EMEA/H/C/WS0965.

	<p>are updated in order to add information on posology and safety in paediatric patients and to reflect the results of the paediatric study.</p> <p>The Package Leaflet is updated in accordance.</p> <p>C.1.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one</p>				
PSUSA/2697/201610	Periodic Safety Update EU Single assessment - sevelamer	09/06/2017	n/a		PRAC Recommendation - maintenance
PSUSA/2697/201510	Periodic Safety Update EU Single assessment - sevelamer	23/06/2016	18/08/2016	SmPC	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2697/201510.
WS/0867	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>Update of section 4.5 of the SmPC regarding drug-drug interaction between sevelamer and proton pump inhibitors. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in section 4.8 of the SmPC of Renvela and Sevelamer carbonate Zentiva in order to harmonize the wording for all Sevelamer compounds.</p> <p>C.1.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	11/02/2016	18/08/2016	SmPC and PL	Changes in gastric acidity with acid suppressants may potentially alter the efficacy of sevelamer HCL. During post-marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer hydrochloride.

WS/0803	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required</p>	19/11/2015	n/a		
WS/0770	<p>This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.</p> <p>C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data</p>	01/10/2015	11/02/2016	SmPC and PL	
IB/0002	B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes	09/04/2015	11/02/2016	SmPC, Labelling and PL	
IAIN/0001	B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings	17/02/2015	11/02/2016	SmPC and PL	